Optibrium Introduces the Latest Release of StarDrop Featuring Card View, a Unique Freeform Environment
Optibrium, a developer of software for drug discovery, has released version 6.0 of its StarDrop software platform. This major new release introduces Card View, an intuitive and highly flexible environment to view and interact with compound data in the context of discovery projects. Card View provides a unique and highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and optimisation strategies for drug discovery. The software further extends StarDrop’s capabilities to reduce the time and cost associated with delivering high quality drug candidates.
Card View presents compound structures and associated data on virtual cards that can be moved and organised with complete freedom, creating ‘links’ and ‘stacks’ to capture relationships and groupings. This enables researchers to explore data in a flexible and interactive way and organise compounds in a manner that mirrors their thought processes. The resulting cards and views can be conveniently annotated and copied to clearly share results and conclusions. Furthermore, Card View provides an ideal environment in which analyses, such as clustering or molecular matched pairs, can be applied to organise compounds and highlight patterns or features that guide further optimisation strategies.
Dr Matthew Segall, Optibrium’s CEO, commented: “Card View is a ground-breaking approach to exploring and organising compound data. It breaks free from the restrictions of chemical spreadsheets and the traditional form views that often make it difficult to find optimal compounds and key structure-activity relationships. Feedback from customers has been overwhelmingly positive, as this novel environment brings researchers a new and interesting dimension in intuitive compound design.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance